Sequence: CKRRMKWKK
| Experiment Id | EXP002261 |
|---|---|
| Paper | Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor c |
| Peptide | CPP (penetratin-derived) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | siVEGF 1 mg/kg |
| Rna Concentration | siVEGF 1 mg/kg |
| Mixing Ratio | fixed in TMPM formulation |
| Formulation Format | polymeric micelle (TMPM) |
| Formulation Components | PTX/siVEGF-CPPs/TMPM |
| Size Nm | 100.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | MCF-7 tumor-bearing nude mice |
| Administration Route | intravenous (tail vein) |
| Output Type | tumor growth inhibition + VEGF knockdown |
| Output Value | tumor regression; ↓ VEGF; PVN destruction; ↑ apoptosis |
| Output Units | |
| Output Notes | qRT-PCR, ELISA, CD31 IHC, TUNEL assay |
| Toxicity Notes | No significant body weight loss (except free PTX) |
| Curation Notes |